C. Gregory, Inflammation and cancer revisited: An hypothesis on the oncogenic potential of the apoptotic tumor cell, Autoimmunity, vol.65, issue.24, pp.312-316, 2013.
DOI : 10.1158/0008-5472.CAN-05-2718

C. Gregory and J. Pound, Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues, The Journal of Pathology, vol.465, issue.2, pp.177-194, 2011.
DOI : 10.1038/nature09141

M. Obeid, T. Panaretakis, N. Joza, R. Tufi, A. Tesniere et al., Calreticulin exposure is required for the immunogenicity of ??-irradiation and UVC light-induced apoptosis, Cell Death and Differentiation, vol.59, issue.10, pp.1848-1850, 2007.
DOI : 10.1016/S0022-1759(02)00069-8

M. Obeid, A. Tesniere, F. Ghiringhelli, G. Fimia, L. Apetoh et al., Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature Medicine, vol.279, issue.1, pp.54-61, 2007.
DOI : 10.1038/nm1523

URL : https://hal.archives-ouvertes.fr/inserm-00451702

M. Obeid, ERP57 Membrane Translocation Dictates the Immunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Calreticulin, The Journal of Immunology, vol.181, issue.4, pp.2533-2543, 2008.
DOI : 10.4049/jimmunol.181.4.2533

M. Obeid, Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptides, Molecular Cancer Therapeutics, vol.8, issue.9, pp.2693-2707, 2009.
DOI : 10.1158/1535-7163.MCT-09-0228

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1?????dependent adaptive immunity against tumors, Nature Medicine, vol.7, issue.10, pp.1170-1178, 2009.
DOI : 10.4049/jimmunol.172.6.3399

URL : https://hal.archives-ouvertes.fr/hal-00419823

L. Apetoh, F. Ghiringhelli, A. Tesniere, A. Criollo, C. Ortiz et al., The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy, Immunological Reviews, vol.10, issue.1, pp.47-59, 2007.
DOI : 10.1016/j.jim.2004.03.013

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz et al., Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007.
DOI : 10.4049/jimmunol.173.1.307

URL : https://hal.archives-ouvertes.fr/hal-00316924

S. Demaria, E. Golden, and S. Formenti, Role of Local Radiation Therapy in Cancer Immunotherapy, JAMA Oncology, vol.1, issue.9, pp.1325-1332, 2015.
DOI : 10.1001/jamaoncol.2015.2756

F. Klug, H. Prakash, P. Huber, T. Seibel, N. Bender et al., Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy, Cancer Cell, vol.24, issue.5, pp.589-602
DOI : 10.1016/j.ccr.2013.09.014

URL : http://doi.org/10.1016/j.ccr.2013.09.014

C. Son, J. Bae, D. Shin, H. Lee, W. Jo et al., Combination Effect of Regulatory T-Cell Depletion and Ionizing Radiation in Mouse Models of Lung and Colon Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.92, issue.2, pp.390-398, 2015.
DOI : 10.1016/j.ijrobp.2015.01.011

Y. Suzuki, K. Mimura, Y. Yoshimoto, M. Watanabe, Y. Ohkubo et al., Immunogenic Tumor Cell Death Induced by Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma, Cancer Research, vol.72, issue.16, pp.3967-3976, 2012.
DOI : 10.1158/0008-5472.CAN-12-0851

URL : http://cancerres.aacrjournals.org/content/canres/72/16/3967.full.pdf

K. Ohba, K. Omagari, T. Nakamura, N. Ikuno, S. Saeki et al., Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis, Gut, vol.43, issue.4, pp.575-577, 1998.
DOI : 10.1136/gut.43.4.575

K. Okuma, H. Yamashita, Y. Niibe, K. Hayakawa, and K. Nakagawa, Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report, Journal of Medical Case Reports, vol.15, issue.17, p.111, 2011.
DOI : 10.1158/1078-0432.CCR-09-0265

P. Wersall, H. Blomgren, P. Pisa, I. Lax, K. Kalkner et al., Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma, Acta Oncologica, vol.58, issue.3, pp.493-497, 2006.
DOI : 10.1016/j.ijrobp.2003.09.012

J. Antoniades, L. Brady, and D. Lightfoot, Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas, International Journal of Radiation Oncology*Biology*Physics, vol.2, issue.1-2, pp.141-147, 1977.
DOI : 10.1016/0360-3016(77)90020-7

D. Kingsley, An interesting case of possible abscopal effect in malignant melanoma, The British Journal of Radiology, vol.48, issue.574, pp.863-866, 1975.
DOI : 10.1259/0007-1285-48-574-863

M. Postow, M. Callahan, C. Barker, Y. Yamada, J. Yuan et al., Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, New England Journal of Medicine, vol.366, issue.10, pp.925-931, 2012.
DOI : 10.1056/NEJMoa1112824

E. Golden, A. Chhabra, A. Chachoua, S. Adams, M. Donach et al., Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial, The Lancet Oncology, vol.16, issue.7, pp.795-803, 2015.
DOI : 10.1016/S1470-2045(15)00054-6

A. Grimaldi, E. Simeone, D. Giannarelli, P. Muto, S. Falivene et al., Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy, OncoImmunology, vol.23, issue.5, p.28780, 2014.
DOI : 10.1158/1078-0432.CCR-09-1624

M. Dewan, A. Galloway, N. Kawashima, J. Dewyngaert, J. Babb et al., Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody, Clinical Cancer Research, vol.15, issue.17, pp.5379-5388, 2009.
DOI : 10.1158/1078-0432.CCR-09-0265

URL : http://clincancerres.aacrjournals.org/content/clincanres/15/17/5379.full.pdf

Y. Akutsu, H. Matsubara, T. Urashima, A. Komatsu, H. Sakata et al., Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice, International Journal of Oncology, vol.31, issue.3, pp.509-515, 2007.
DOI : 10.3892/ijo.31.3.509

K. Shiraishi, Y. Ishiwata, K. Nakagawa, S. Yokochi, C. Taruki et al., Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1??, Clinical Cancer Research, vol.14, issue.4, pp.1159-1166, 2008.
DOI : 10.1158/1078-0432.CCR-07-4485

T. Takeshima, K. Chamoto, D. Wakita, T. Ohkuri, Y. Togashi et al., Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy, Cancer Research, vol.70, issue.7, pp.2697-2706, 2010.
DOI : 10.1158/0008-5472.CAN-09-2982

S. Demaria, B. Ng, M. Devitt, J. Babb, N. Kawashima et al., Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.862-870, 2004.
DOI : 10.1016/j.ijrobp.2003.09.012

L. Deng, H. Liang, B. Burnette, M. Beckett, T. Darga et al., Irradiation and anti???PD-L1 treatment synergistically promote antitumor immunity in mice, Journal of Clinical Investigation, vol.124, issue.2, pp.687-695, 2014.
DOI : 10.1172/JCI67313DS1

URL : http://www.jci.org/articles/view/67313/files/pdf

J. Zeng, A. See, J. Phallen, C. Jackson, Z. Belcaid et al., Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas, International Journal of Radiation Oncology*Biology*Physics, vol.86, issue.2, pp.343-349, 2013.
DOI : 10.1016/j.ijrobp.2012.12.025

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963403

. Twyman-saint, C. Victor, A. Rech, A. Maity, R. Rengan et al., Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature, vol.67, issue.7547, pp.373-377, 2015.
DOI : 10.1007/s00285-012-0589-7

A. Filatenkov, J. Baker, A. Muller, G. Ahn, H. Kohrt et al., Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion, Radiation Research, vol.182, issue.2, pp.163-169, 2014.
DOI : 10.1667/RR13471.1

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.
DOI : 10.1056/NEJMoa1003466

S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, D. Smith et al., Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, pp.2443-2454
DOI : 10.1056/NEJMoa1200690

J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian et al., Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-2465, 2012.
DOI : 10.1056/NEJMoa1200694

M. Postow, J. Chesney, A. Pavlick, C. Robert, K. Grossmann et al., Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, New England Journal of Medicine, vol.372, issue.21, pp.2006-2017, 2015.
DOI : 10.1056/NEJMoa1414428

M. Hellmann, N. Rizvi, J. Goldman, S. Gettinger, H. Borghaei et al., Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, The Lancet Oncology, vol.18, issue.1, pp.31-41, 2017.
DOI : 10.1016/S1470-2045(16)30624-6

S. Antonia, J. Lopez-martin, J. Bendell, P. Ott, M. Taylor et al., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.7, pp.883-895, 2016.
DOI : 10.1016/S1470-2045(16)30098-5

S. Antonia, S. Goldberg, A. Balmanoukian, J. Chaft, R. Sanborn et al., Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, The Lancet Oncology, vol.17, issue.3, pp.299-308, 2016.
DOI : 10.1016/S1470-2045(15)00544-6

P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small et al., Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, New England Journal of Medicine, vol.363, issue.5, pp.411-422, 2010.
DOI : 10.1056/NEJMoa1001294

G. Rabinovich, D. Gabrilovich, and E. Sotomayor, Immunosuppressive Strategies that are Mediated by Tumor Cells, Annual Review of Immunology, vol.25, issue.1, pp.267-296, 2007.
DOI : 10.1146/annurev.immunol.25.022106.141609

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895922

M. Colombo and G. Trinchieri, Interleukin-12 in anti-tumor immunity and immunotherapy, Cytokine & Growth Factor Reviews, vol.13, issue.2, pp.155-168, 2002.
DOI : 10.1016/S1359-6101(01)00032-6

A. Sedlar, S. Kranjc, T. Dolinsek, M. Cemazar, A. Coer et al., Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma, BMC Cancer, vol.46, issue.1, p.38, 2013.
DOI : 10.2478/v10019-012-0035-x

V. Berg, J. Vrohlings, M. Haller, S. Haimovici, A. Kulig et al., Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell???mediated glioma rejection, The Journal of Experimental Medicine, vol.90, issue.13, pp.2803-2811, 2013.
DOI : 10.1158/0008-5472.CAN-05-1682

R. Heller, Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma, J Clin Oncol, vol.26, issue.36, pp.5896-5903, 2008.

G. Sersa, J. Teissie, M. Cemazar, E. Signori, U. Kamensek et al., Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer, Cancer Immunology, Immunotherapy, vol.34, issue.1, pp.1315-1327, 2015.
DOI : 10.1007/s10439-005-9076-2

G. Linette, O. Hamid, E. Whitman, J. Nemunaitis, J. Chesney et al., A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma, ASCO Annual Meeting Abstracts, 2013.

R. Danielli, R. Patuzzo, D. Giacomo, A. Gallino, G. Maurichi et al., Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study, Cancer Immunology, Immunotherapy, vol.15, issue.23, pp.999-1009, 2015.
DOI : 10.1158/1078-0432.CCR-09-1624

M. Cemazar, A. Avgustin, J. Pavlin, D. Sersa, G. Poli et al., Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours, Veterinary and Comparative Oncology, vol.62, issue.2, 2016.
DOI : 10.1111/j.1476-5829.2011.00301.x

T. Lu, R. Ramakrishnan, S. Altiok, J. Youn, P. Cheng et al., Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice, Journal of Clinical Investigation, vol.121, issue.10, pp.4015-4029, 2011.
DOI : 10.1172/JCI45862DS1